MAIWALD
INTELLECTUAL
PROPERTY

Contact
T +49 (0)211 301 257 0
F +49 (0)211 301 257 11
E Grabow@maiwald.eu

Dr. Gisela Grabow

Counsel
Lawyer (England/Wales)

Gisela is particularly active in international legal issues involving contractual, cross-border, regulatory and EU matters in the pharmaceutical, biotech, foodstuff, medical devices and automotive sectors.

She has more than ten years of experience, in particular in negotiating (international) agreements, from development cooperations to product cycle contracts, patent portfolio sales, manufacturing contracts, contracts relating to marketing authorisations and licence agreements. She also provides comprehensive advice in due diligences.

She studied law at universities in England, Germany and Den Haag. After her studies, she worked as a legal trainee for law firms in Germany and London, and then as a temporary Lawyer (foreign services) in Texas, USA and at an international organisation. Gisela specialised, inter alia, in international and European commercial law, including IP law, and international and European law on dispute resolution (settlement of cross-border disputes) during her graduate and postgraduate studies LL.M.) as well as for her PhD.

Gisela also worked in Legal Consultant positions at an international organisation. As president of a European legal commission, she regularly publishes comments on legislative proposals of the EU Commission and monitors changes in EU law.

CAREER

since 2022	Counsel at Maiwald
2019 - 2022	Principal at Maiwald
2015 - 2019	Senior Associate at Maiwald
2011 - 2015	Associate at Maiwald
2008 - 2011	Legal traineeship and legal consultant positions at an international organisation

EDUCATION

2016	Doctoral studies (Dr. iur.) in Germany and England
2009 - 2011	Legal traineeship and Temporary Lawyer (Foreign Services) in Texas

2009	Graduate and Postgraduate Studies in Law at universities in Germany, England and the Netherlands, examinations and LPC

PRACTICE AREAS

- 药品法
- 合规
- 商标&外观设计
- 竞争&反垄断法
- 合同法

SERVICES

- Negotiation and drafting of international contracts
- EU regulatory affairs (pharma, medical devices, biotech and food)
- Support in cross-border cartel and competition law proceedings
- Legal and IP Due Diligence

PUBLICATIONS

- EU seeks harmonisation of privilege for generic market entry, Managing IP 2024
- EU pharmaceutical reforms propose changes to regulatory protection periods, Managing IP 2024
- Proposed regulations for a unitary SPC for medicinal products under the microscope, Managing IP 2024
- Ergänzende Schutzzertifikate für Arzneimittel, EuZW 2023, 643
- A path towards a crisis-proof EU pharmaceutical legislation? The European Commission proposal, MIP 2023
- Quo vadis Arzneimittelrecht – ein Überblick zur Überarbeitung der EU-Arzneimittelvorschriften, PharmR 6/2023
- Ergänzende Schutzzertifikate – Überblick und Ausblick zur EU-Initiative, Arzneimittel & Recht, 2022
- EU-Initiative zu Zwangslizenzen – Chance oder Wettbewerbsnachteil? Arzneimittel & Recht, 2022
- Alignment of Pharmaceutical Strategy for Europe with the Action Plan on IP, 2021
- EMA and EU Commission offer flexibility instead of intervention, 2020
- Proposed Regulation Increasing Transparency at the EFSA Threatens IP, 2019
- EU Commission Consultation on „Measures on animal cloning for food production in the EU“, Regulation No. 258/97 concerning novel foods and novel food ingredients
- EU Commission Consultation on ‘Genetically modified crops’
- EU Commission Consultation on a possible extension of geographical indication protection of the European Union to non-agricultural products which is named “Making the most out of Europe’s traditional know-how”
- „A review of the EU regime for the fruit and vegetables sector – public consultation on policy options and their impact assessment“
- EU Commission consultation on “Evaluation of the activities of the EU Intellectual Property Office related to enforcement and the European Observatory on Infringements of Intellectual Property Rights (Regulation No 386/2012)”
- EU Consultation on the Report and Analysis of the Application of Directive 2004/48/EC

LANGUAGES

- German and English (bilingual)
- French